* Ventyx Biosciences Inc reported a quarterly adjusted loss of 50 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -92 cents. The mean expectation of eight analysts for the quarter was for a loss of 52 cents per share. Wall Street expected results to range from -62 cents to -43 cents per share.
* Reported revenue was zero; analysts expected zero.
* Ventyx Biosciences Inc's reported EPS for the quarter was a loss of 50 cents.
* The company reported a quarterly loss of $35.25 million.
* Ventyx Biosciences Inc shares had risen by 6.9% this quarter and lost 5.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 3.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Ventyx Biosciences Inc is $10.00 This summary was machine generated from LSEG data November 8 at 04:20 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.52 -0.50 Beat
Jun. 30 2024 -0.58 -0.45 Beat
Mar. 31 2024 -0.69 -0.62 Beat
Dec. 31 2023 -0.90 -0.79 Beat
Comments